Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Primary Objective: * To estimate the proportion of patients with donor derived engraftment at day 100 post transplant as defined by 80% or greater donor cells in the CD3 (T cell) fraction Secondary Objectives: * To determine the incidence and severity of graft-versus-host disease (GVHD) by day 100 * To determine the incidence of peri-transplant mortality (death by day 100) * To monitor donor cell chimerism at various time points following allogeneic transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months and yearly for 5 years.